IRON CLEARANCE BY TRANSFERRIN HALF-MOLECULES

Information

  • Research Project
  • 3501935
  • ApplicationId
    3501935
  • Core Project Number
    R43HL046035
  • Full Project Number
    1R43HL046035-01
  • Serial Number
    46035
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/15/1991 - 35 years ago
  • Project End Date
    1/14/1992 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    4/15/1991 - 35 years ago
  • Budget End Date
    1/14/1992 - 34 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/10/1991 - 35 years ago

IRON CLEARANCE BY TRANSFERRIN HALF-MOLECULES

DESCRIPTION: (Adapted from the investigator's abstract). The hypothesis to be tested is that the 40 kDA, half-molecules of transferrin are capable of binding excess iron in parenchymally or reticuloendothelially iron overloaded liver cells in culture and in mice and eliminating this bound iron into the medium or via the kidney. Human or rat hepatoma cells in culture will be iron loaded. The relative efficiencies of iron removal from these cells by (a) deferoxamine, (b) holoapotransferrins and (c) apotransferrin half-molecules separately and in combination, will be compared. Adult mice will be iron loaded by hypertransfusion or by feeding a high iron diet. The relative efficiencies of iron clearance in normal, hypertransfused and dietarily iron loaded mice in (a) non-treated controls, (b) animals infused with deferrioxamine and (c) animals infused with various apotransferrin half- molecules, will be compared. The potential for technological innovation and commercial application in Phase II would be the development of a "synthetic organ" for implantation in persons with ongoing transfusional iron overload e.g., thalassemics. This organ would be designed, to produce from body fluids, a steady supply of recombinant human transferrin hald-molecule(s) for binding excess iron and excreting it in the urine.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    HAEMATOLOGIC TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    192057123
  • Organization City
    ESSEX JUNCTION
  • Organization State
    VT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    05452
  • Organization District
    UNITED STATES